Alpha Cognition Inc.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial-stage biopharmaceutical company dedicated to developing transformative treatments for neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), where limited or no approved treatment options currently exist.

Products & Services

ZUNVEYL (benzgalantamine):A cholinesterase inhibitor approved for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

Specialties

Neurodegenerative diseases Alzheimer's disease treatments Cognitive Impairment with mild Traumatic Brain Injury (mTBI)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 35000000 MR: - FA: 35.0 million FAN: 35000000	D: 2025-09-30 FD: 2025-09-30	3 investors
2	RT: Public Offering T: - FT: Public Offering	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2024-11-12 FD: 2024-11-12	1 investors
3	RT: Convertible Note and Warrants Bridge Financing T: - FT: Convertible Note and Warrants Bridge Financing	A: 4454000 MR: - FA: $4.454 Million FAN: 4454000	D: 2024-10-01 FD: 2024-10-01	4 investors
4	RT: Convertible Note and Warrants Bridge Financing T: - FT: Convertible Note and Warrants Bridge Financing	A: 4545000 MR: - FA: $4.545 million FAN: 4545000	D: 2024-09-24 FD: 2024-09-24	4 investors
5	RT: Private Placement T: - FT: Private Placement	A: 8450000 MR: - FA: US$8.45 million FAN: 8450000	D: 2024-01-19 FD: 2024-01-19	-
6	RT: Private Placement T: - FT: Private Placement	A: 2011138 MR: - FA: US$2,011,138 FAN: 2011138	D: 2023-12-22 FD: 2023-12-22	-
7	RT: Private Placement T: - FT: Private Placement	A: 6500000 MR: - FA: US$6.5 million FAN: 6500000	D: 2023-12-04 FD: 2023-12-04	-
8	RT: Private Placement T: - FT: Private Placement	A: 1009999 MR: - FA: US$1,009,999 FAN: 1009999	D: 2023-11-08 FD: 2023-11-08	-
9	RT: Private Placement T: - FT: Private Placement	A: 351303 MR: - FA: US$351,303 FAN: 351303	D: 2023-10-16 FD: 2023-10-16	-
10	RT: Private Placement T: - FT: Private Placement	A: 6500000 MR: - FA: $6,500,000 FAN: 6500000	D: 2023-05-30 FD: 2023-05-30	-

Public Offering Latest

2025-09-30

$35.0M

3 investors (Pro only)

Public Offering 2024-11-12

$50.0M

Convertible Note and Warrants Bridge Financing 2024-10-01

$4.5M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Michael McFadden

CEO and Director

L

Lauren D'Angelo

Chief Operating Officer

H

Henry Du

Vice President, Finance and Accounting

D

Denis Kay

Chief Scientific Officer

R

Robert Lynch

Investor Relations Contact

J

Jeffrey L. Cummings

MD, ScD

View 30 more team members with Pro

Unlock Full Team Directory

Recent News